Abbott Laboratories
NYSE:ABTMedical - Devices
-$0.51 today
- Market cap
- $180.95B
- Beta
- 0.62
- P/E (TTM)
- 24.5
- EPS (TTM)
- $3.59
- Dividend yield
- 2.77%
Volume 7.02M
Average 13.17M
ABT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Abbott LaboratoriesNYSE: ABT
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures turns positive
Q2 FY2026 capital expenditures was $399M, compared with -$502M a year earlier. Trailing-twelve-month capital expenditures was -$1.19B. Over 3 fiscal years it compounded at +6.9% a year.
Context
- Capital expenditures amounted to 4.9% of revenue in FY2025, down 0.4 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly capital expenditures holds near $399M or moves back toward the trailing-twelve-month quarterly average of -$296.25M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (2.17B) USD
- Year-over-year change
- +1.6%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.17B) | +1.6% |
| FY2024 | 2024-12-31 | (2.21B) | -0.2% |
| FY2023 | 2023-12-31 | (2.2B) | -23.9% |
| FY2022 | 2022-12-31 | (1.78B) | +5.7% |
| FY2021 | 2021-12-31 | (1.89B) | — |
Capital Expenditures vs competitors
How ABT compares with its peers on the latest reported figures
- ABT's LTM Jun 2026 capital expenditures of $1.19B is the 4th largest of the 10 companies compared; the peer median is $904M.
- Its year-over-year change of -47.6% is the lowest of 10, against a peer median of +8.6%.
- Capital expenditures amounts to 2.5% of revenue for ABT, versus a peer median of 4.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $5.57B | +8.6% | +6.4% | 5.6% | |
| LTM Jul 2026 | $1.9B | +3.3% | +9.3% | 5.1% | |
| LTM Sep 2026 | $1.73B | +12.2% | -12.1% | 3.6% | |
| LTM Jun 2026 | $1.19B | -47.6% | +6.9% | 2.5% | |
| LTM Sep 2026 | $1.13B | -13.0% | +0.1% | 4.4% | |
| LTM Jun 2026 | $904M | -7.2% | +12.7% | 4.3% | |
| LTM Jun 2026 | $823M | +10.9% | +9.0% | 3.2% | |
| LTM Sep 2026 | $672M | -11.6% | -8.4% | 3.3% | |
| LTM Jun 2026 | $522M | +21.4% | +15.8% | 2.6% | |
| LTM Jun 2026 | $286.7M | +53.3% | -0.6% | 4.4% | |
| Peer median (excluding ABT) | $904M | +8.6% | +6.4% | 4.3% | |
Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 7.07B | 6.93B | 5.72B | 13.4B | 6.52B |
| Depreciation & Amortization | 3.54B | 3.27B | 3.24B | 3.22B | 3.12B |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 640M | 685M | 644M | 673M | 664M |
| Change in Working Capital | (771M) | (1.52B) | (2.48B) | (9.22B) | (803M) |
| Accounts Receivables | (383M) | (68M) | (356M) | (691M) | (652M) |
| Inventory | (456M) | (1.41B) | (232M) | (58M) | 195M |
| Accounts Payables | 1.29B | 420M | (760M) | 356M | 954M |
| Other Working Capital | (1.22B) | (458M) | (1.13B) | (8.82B) | (1.3B) |
| Other Non-Cash Items | 55M | 215M | 126M | 482M | 65M |
| Operating Cash Flow | 10.53B | 9.58B | 7.26B | 8.56B | 9.57B |
| Capital Expenditures | (1.89B) | (1.78B) | (2.2B) | (2.21B) | (2.17B) |
| Acquisitions (Net) | (53M) | 48M | (837M) | 1M | (105M) |
| Purchases of Investments | (173M) | (185M) | (159M) | (169M) | (167M) |
| Sales of Investments | 77M | 152M | 43M | 28M | 3M |
| Other Investing Activities | 26M | 22M | 22M | 9M | 18M |
| Investing Cash Flow | (2.01B) | (1.74B) | (3.13B) | (2.34B) | (2.42B) |
| Debt Repayment | (248M) | (699M) | (2.48B) | (537M) | (1.61B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 396M |
| Common Stock Repurchased | (2.3B) | (3.8B) | (1.23B) | (1.3B) | (893M) |
| Dividends Paid | (3.2B) | (3.31B) | (3.56B) | (3.84B) | (4.12B) |
| Other Financing Activities | 255M | 167M | 167M | 264M | (82M) |
| Financing Cash Flow | (5.49B) | (7.64B) | (7.09B) | (5.4B) | (6.31B) |
| Effect of Forex Changes | (70M) | (122M) | (23M) | (96M) | 71M |
| Net Change in Cash | 2.96B | 83M | (2.99B) | 720M | 906M |
| Free Cash Flow | 8.65B | 7.8B | 5.06B | 6.35B | 7.4B |
Abbott Laboratories
NYSE:ABT
Intrinsic Alpha fair value
Locked
Current Price
$104.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.